Article

Adoption of Biosimilars: Prescriber, Pharmacy and Payer Perspectives

This activity is supported by educational funding provided by Amgen and Merck Sharp & Dohme Corp.

On-demand 4-part Medical Crossfire

Adoption of Biosimilars: Prescriber, Pharmacy and Payer Perspectives

Activity Overview

This 4-part online CE-accredited activity will serve as an update on the clinical options in Biosimilars and the changing environment for clinicians, specialty pharmacists, and payers. To view each activity, click on the hyperlinks below.

Part 1: Overview of the Biosimilar Review Process: Evaluating Biosimilar Safety, and Bioequivalence

Part 2: Clinical Adoption of Biosimilars: Prescriber Viewpoint

Part 3: A Managed Care and Population Health Perspective of Biosimilars

Part 4: Access to Biosimilars: The Role of the Specialty Pharmacy

Related Videos
James Chambers, PhD
Kirollos Hanna, PharmD
A panel of 4 experts on biosimilars
dr kimberly maxfield
Dr. Jorge Garcia
dr kimberly maxfield
Bincy Abraham, MD
Screenshot of Christine Pfaff, RPh, during a Zoom video interview
Related Content
FDA approval with stamp. | Image Credit: Surendra - stock.adobe.com
December 20th 2024

FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara

Cameron Santoro
The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.
managed care cast banner
August 17th 2022

How Health Care Institutions Can Leverage Biosimilars to Generate Savings

Skylar Jeremias
On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Seattle Washington skyline | Image Credit: © espiegle - stock.adobe.com
December 12th 2024

From Approval to Practice: Addressing the Hurdles in Biosimilar Integration

Skylar Jeremias
Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.
Managed Care Cast
June 14th 2022

Biosimilar Whisky? This Expert Says It’s Doable, No Aging Required

On this episode of Managed Care Cast, we’re highlighting a hobby from a biosimilar expert who says he can make whisky more accessible and affordable through—you guessed it—his own biosimilar whisky.
FDA approval. | Image Credit: syahrir - stock.adobe.com
December 2nd 2024

FDA Approves Sixth Ustekinumab Biosimilar, Yesintek

Skylar Jeremias
The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with various immunology conditions, including psoriatic arthritis and inflammatory bowel disease.
Patient access to medication. | Image Credit: Supatman - stock.adobe.com
November 22nd 2024

Addressing Patent Hurdles, Payer Barriers, and Interchangeability

Cameron Santoro
Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo